Cargando…
Systemic and Intralesional Bevacizumab in Juvenile Onset Recurrent Respiratory Papillomatosis: A Report of Two Cases
Recurrent respiratory papillomatosis (RRP) is a stubborn disease. Despite volumes of researches done for a definite cause and management, the scientific community offers only theories for causation and options for treatments. Bevacizumab has emerged as a promising solution to the fear of sufferers o...
Autores principales: | Goyal, Arun, Kapoor, Dhruv, Saha, Richa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372222/ https://www.ncbi.nlm.nih.gov/pubmed/34426784 http://dx.doi.org/10.1007/s12070-021-02814-3 |
Ejemplares similares
-
Recurrent Respiratory Papillomatosis (RRP)—Juvenile Onset
por: Dyrstad, Sara W., et al.
Publicado: (2008) -
Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis
por: Wierzbicka, Małgorzata, et al.
Publicado: (2011) -
Systemic Bevacizumab for Severe Recurrent Respiratory Papillomatosis
por: Tatineni, Swetha, et al.
Publicado: (2022) -
Estimated incidence of juvenile-onset recurrent respiratory papillomatosis in Korea
por: Oh, Jin-Kyoung, et al.
Publicado: (2021) -
Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis
por: MOHR, MICHAEL, et al.
Publicado: (2014)